Biotest AG and AERES Biomedical Successfully Complete Engineering of the Antibody BT-062
In a collaborative research effort AERES Biomedical, Ltd. and Biotest AG successfully completed the engineering of the monoclonal antibody BT-062. The candidate is directed against a tumor-specific target expressed by multiple myeloma and is in development for this life-threatening tumour of the blood.
After BT-062 had shown impressive efficacy in an animal model of the disease, this is an important step towards the clinical development of the candidate. With tolerability and early efficacy displayed by BT-061 and BT-063 in patients with rheumatoid arthritis and systemic lupus erythematosus, respectively, BT-062 will be Biotest´s third monoclonal antibody entering clinical trials.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.